Basic Research
Copyright ©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jan 28, 2008; 14(4): 554-562
Published online Jan 28, 2008. doi: 10.3748/wjg.14.554
Table 1 Overview of biomarkers’ expression level in the 2 000-20 000 m/z mass range in wild-type cagA, phosphorylation site mutant cagA and blank vector transfected AGS cells
Array typem/zPeak intensity (mean ± SD)
Fold change
Comments
VWMW vs VM vs V
SAX2201330.39 ± 7.198.82 ± 5.3729.92 ± 9.53-3.45a-1.02CagA phosphorylation dependent
42865.08 ± 0.852.25 ± 0.704.44 ± 0.58-2.26a-1.14
85649.73 ± 1.883.72 ± 0.4210.86 ± 1.77-2.62a1.12
90842.61 ± 1.356.13 ± 1.742.75 ± 0.602.35a1.05
99525.22 ± 2.072.51 ± 0.955.19 ± 1.30-2.08a-1.01
11 6433.39 ± 0.981.32 ± 0.863.70 ± 1.10-2.57a1.09
CM1042294.29 ± 0.579.36 ± 0.326.13 ± 0.782.18a1.43
51303.59 ± 0.726.93 ± 0.614.58 ± 0.461.93a1.28
81624.26 ± 0.388.88 ± 1.064.97 ± 0.242.08a1.17
11 0873.37 ± 0.751.94 ± 0.463.19 ± 0.39-1.74a-1.06
13 8042.97 ± 0.798.66 ± 0.484.14 ± 1.232.92a1.39
14 0213.06 ± 0.245.59 ± 0.413.66 ± 1.041.83a1.20
SAX265453.08 ± 0.886.95 ± 1.345.53 ± 0.692.26a1.80aCagA phosphorylation independent
CM10471410.16 ± 1.2617.95 ± 3.6117.31 ± 1.411.77a1.70a
472911.11 ± 1.7520.51 ± 4.0221.92 ± 2.581.80a1.97a
66569.67 ± 2.4522.83 ± 4.2721.46 ± 1.922.36a2.22a
Table 2 Comparison of biomarkers’ expression level under mitogen-activated protein kinase kinase (MEK) inhibitor free, treated and DMSO treated conditions
Arraym/zInhibitor free
Inhibitor treated
DMSO treated
Comments
typeFold change (W vs V)P-valueFold change (W+I vs V+I)P-valueFold change (W+D vs V+D)P-value
SAX290841.640.0211.000.8272.210.021Caused by ERK1/2 activation
CM1042292.250.0211.071.0002.440.021
81621.710.021-1.150.1491.810.021
SAX22013-1.990.0211.160.1491.030.773Have no relationship with ERK1/2 activation
4286-3.500.021-2.140.021-1.950.021
65452.860.0212.390.0212.000.021
8564-3.050.021-2.960.021-1.850.021
9952-3.350.021-2.870.021-2.620.021
11 643-1.710.021-2.490.021-2.380.021
CM1047141.890.0211.680.0431.740.021
47291.990.0211.720.0211.860.021
51301.670.0211.660.0212.910.021
66562.120.0212.310.0212.440.021
11 087-1.720.021-1.850.021-1.520.021
13 8042.230.0212.560.0212.600.021
14 0211.980.0211.790.0211.610.021
Table 3 Swiss-Prot and TrEMBL database searching results of the three ERK related biomarkers
BiomarkerMeaningful matching information in Swiss-Prot and TrEMBL database
Comments
(Mw)Protein NameMwpI
9084 (SAX2)BIM-alpha3 (BCL2-like 11 transcript variant 10, chain 1-79)90815.42Over-expression of BIM-alpha3 results in cell apoptosis
EP2E (chain 1-80)90917.55Part of the protein sequences homologous to β-defensins, a family of antimicrobial peptides.
UPF0197 protein (C11orf10 chain 1-79)90795.58Expressed in CD34+ hematopoietic stem/progenitor cells
4229 (CM10)Chromogranin-A Precursor (ER-37, chain 420-456)42334.59Neuroendocrine and endocrine secretory granules, considered as biomarkers in some human cancers
8162 (CM10)Small-inducible cytokine B6 Precursor (chain 40-114)81629.74Functional characterization as chemokines, chemotactic for neutrophil granulocytes
Putative microRNA host gene protein 1 (chain 1-70)81639.25Highly expressed in B-cell lymphoma and lung cancer and enhanced cell proliferation
PNAS-145 (Chain: 1-68)816111.24Human acute promyelocytic leukemia cell line NB4’s apoptosis/differentiation related genes